Caprion to Present Immune Response Results from Phase 1 Study in Ovarian Cancer Patients at 2014 AACR Annual Meeting.

Multiparametric flow cytometry has proven to be the tool of choice for immune profiling in cancer patients following treatment with a vaccine and an immune modulating drug.

Montreal, Canada: April 3, 2014—Caprion, announced today that its immune monitoring business unit, ImmuneCarta®, will present a poster in conjunction with research collaborator, Immunovaccine, detailing immune response results from a Phase 1 study of DPX-Survivac in ovarian cancer patients. Data will be presented at the 2014 American Association of Cancer Research (AACR) Annual Meeting April 5-9, in San Diego, CA.

Abstract Control #6736/Abstract Number #CT411
Immune profiling of patients vaccinated with the survivin targeted therapeutic vaccine DPX-Survivac demonstrates durable polyfunctional CD4+ and CD8+ T cells in ovarian cancer patients.

Wednesday, April 9th, 8AM-12PM
Session ID: Clinical Trials 3
Session Title: Early Phase Clinical Trials 2
Location: Hall A-E
Poster Section: 38
Poster Board Number: 11

The poster and data will describe the use of flow cytometry-based immune monitoring in ovarian cancer patients vaccinated with DPX-Survivac. Information will be presented by Yoav Peretz, Ph.D., Scientific Director for ImmuneCarta.

Marc Mansour, Ph.D., chief operating officer of Immunovaccine, stated, “The flow cytometry-based immune monitoring performed by ImmuneCarta has added significant value to our clinical program by clearly demonstrating the mechanism of action of our DPX-Survivac vaccine in cancer patients.”

Martin LeBlanc, president and CEO of Caprion, commented, "We are pleased to share results from our on-going collaboration with Immunovaccine which we believe demonstrate the valuable immunological insights that ImmuneCarta’s expertise in multiparametric flow cytometry can provide to biotechnology and pharmaceutical companies engaged in the clinical development of therapeutic vaccines and other immunotherapies for the treatment of cancer."
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvants to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.

About Caprion Inc.
Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta®, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta® to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners.
For more information, please visit www.caprion.com.